- Home
- ABOS vs MOLN Comparison
ABOS vs MOLN Comparison
Compare ABOS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | MOLN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 147.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABOS | MOLN |
|---|---|---|
| Price | $1.68 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.60 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 547.5K | 2.0K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $3.52 |
| 52 Week High | $3.60 | $5.36 |
Technical Indicators
Market Signals| Indicator | ABOS | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 26.69 | 36.40 |
| Support Level | $1.67 | N/A |
| Resistance Level | $2.77 | $4.59 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 10.00 | 5.13 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.